MGMT and glioblastoma: This highly targeted, site-specific delivery proves the added benefit of limiting the AMON-mediated silencing to only the ‘in-field’ site of radiation (that is, the tumor), thus decreasing toxic side effects of systemic MGMT inhibition, and being clinically applicable, as RT is standard of care in the treatment of glioblastoma.1, 25 We demonstrated that the use of non-ablative radiation enhances the delivery of unmodified morpholinos both in vitro and in vivo.